CY2016006I2 - Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους - Google Patents

Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους

Info

Publication number
CY2016006I2
CY2016006I2 CY2016006C CY2016006C CY2016006I2 CY 2016006 I2 CY2016006 I2 CY 2016006I2 CY 2016006 C CY2016006 C CY 2016006C CY 2016006 C CY2016006 C CY 2016006C CY 2016006 I2 CY2016006 I2 CY 2016006I2
Authority
CY
Cyprus
Prior art keywords
valsartan
calcium channel
combined use
therapeutic purposes
channel blockers
Prior art date
Application number
CY2016006C
Other languages
English (en)
Other versions
CY2016006I1 (el
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016006(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of CY2016006I1 publication Critical patent/CY2016006I1/el
Publication of CY2016006I2 publication Critical patent/CY2016006I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Steroid Compounds (AREA)
CY2016006C 1998-07-10 2016-03-07 Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους CY2016006I2 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11389398A 1998-07-10 1998-07-10
EP99934647A EP1096932B1 (en) 1998-07-10 1999-07-09 Antihypertensive combination of valsartan and calcium channel blocker
EP07105179A EP1870098A3 (en) 1998-07-10 1999-07-09 Combined use of valsartan and calcium channel blockers for therapeutic purposes

Publications (2)

Publication Number Publication Date
CY2016006I1 CY2016006I1 (el) 2016-10-05
CY2016006I2 true CY2016006I2 (el) 2016-10-05

Family

ID=22352165

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20071101384T CY1107779T1 (el) 1998-07-10 2007-10-25 Αντιυπερτασικος συνδυασμος βαλσαρτανης και παρεμποδιστη διαυλου ασβεστιου
CY200700026C CY2007026I2 (el) 1998-07-10 2007-10-30 Αντιυπερτασικος συνδυασμος βαλσαρτανης και παρεμποδιστη διαυλου ασβεστιου
CY20151100890T CY1116770T1 (el) 1998-07-10 2015-10-06 Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους
CY2016006C CY2016006I2 (el) 1998-07-10 2016-03-07 Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20071101384T CY1107779T1 (el) 1998-07-10 2007-10-25 Αντιυπερτασικος συνδυασμος βαλσαρτανης και παρεμποδιστη διαυλου ασβεστιου
CY200700026C CY2007026I2 (el) 1998-07-10 2007-10-30 Αντιυπερτασικος συνδυασμος βαλσαρτανης και παρεμποδιστη διαυλου ασβεστιου
CY20151100890T CY1116770T1 (el) 1998-07-10 2015-10-06 Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους

Country Status (31)

Country Link
EP (3) EP1870098A3 (el)
JP (1) JP2002520274A (el)
KR (2) KR20040078140A (el)
CN (2) CN1733307A (el)
AT (1) ATE371448T1 (el)
AU (1) AU753486B2 (el)
BE (1) BE2016C011I2 (el)
BR (1) BR9912021A (el)
CA (2) CA2678722C (el)
CY (4) CY1107779T1 (el)
CZ (2) CZ299429B6 (el)
DE (2) DE69936992T2 (el)
DK (2) DK1096932T3 (el)
ES (2) ES2289814T3 (el)
FR (1) FR16C0008I2 (el)
HU (1) HU229383B1 (el)
ID (1) ID27664A (el)
IL (3) IL140665A0 (el)
LU (2) LU91358I2 (el)
NL (2) NL300290I2 (el)
NO (2) NO331802B1 (el)
NZ (2) NZ509260A (el)
PL (1) PL194604B1 (el)
PT (2) PT1096932E (el)
RU (3) RU2243768C2 (el)
SG (1) SG142116A1 (el)
SI (2) SI2322174T1 (el)
SK (1) SK285863B6 (el)
TR (1) TR200100062T2 (el)
WO (1) WO2000002543A2 (el)
ZA (1) ZA200100232B (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK285863B6 (sk) 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
HK1038888B (en) * 1998-12-23 2007-09-21 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
CN1172719C (zh) * 1999-04-28 2004-10-27 武田药品工业株式会社 单纯性视网膜病或前增殖性视网膜病的预防剂、治疗剂、发展抑制剂
DE60037192T2 (de) * 1999-07-21 2008-05-15 Takeda Pharmaceutical Co. Ltd. Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
CN1268331C (zh) 1999-08-30 2006-08-09 萨诺费－阿文蒂斯德国有限公司 肾素－血管紧张素系统抑制剂在制备预防心血管疾病的药物中的用途
AU2001235363A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Mibefradil analogues and their use
WO2001062741A1 (en) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Tetrahydronaphtalene derivatives and their use
AU7393801A (en) * 2000-04-12 2001-10-23 Novartis Ag Combination of organic compounds
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
WO2002053147A1 (es) * 2000-12-29 2002-07-11 Osmotica Corp. Composicion farmaceutica para el tratamiento de la enfermedad cerebrovascular cognitiva
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
CA2463758A1 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
WO2004110354A2 (en) 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
AU2004238546A1 (en) * 2003-05-16 2004-11-25 Novartis Ag Pharmaceutical composition comprising valsartan
RU2255740C2 (ru) * 2003-07-02 2005-07-10 Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Способ подбора дозы дилтиазема для лечения больных постинфарктным кардиосклерозом с недостаточностью кровообращения 2 функционального класса
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
US20050209288A1 (en) * 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
EP1874311B1 (en) 2005-04-15 2011-10-05 Research & Innovation S.p.A. A method for preventing, delaying or reverting abnormal amyloid deposition
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
US20080261958A1 (en) * 2005-11-08 2008-10-23 Randy Lee Webb Combination of Organic Compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2329805C2 (ru) * 2006-08-28 2008-07-27 Илья Николаевич Медведев Способ стабилизации эндотелиальной выстилки сосудов у больных метаболическим синдромом
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
RU2338527C1 (ru) * 2007-02-26 2008-11-20 Илья Николаевич Медведев Способ коррекции высокой эндотелиоцитемии у лиц с метаболическим синдромом
DK2214666T3 (da) 2007-10-05 2014-01-27 Alzheimer S Inst Of America Inc Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer
CN101433536A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和沙坦类药物的治疗组合物
BRPI0821455A2 (pt) * 2007-12-31 2015-06-16 Lupin Ltd Composições farmacêuticas de amlopidina e valsartan
US20100137403A1 (en) * 2008-07-10 2010-06-03 Scott Malstrom Method for enhancing cognition or inhibiting cognitive decline
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
RU2398581C1 (ru) * 2009-05-28 2010-09-10 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий) Способ лечения больных гипертрофической кардиомиопатией
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
WO2012141385A1 (en) 2011-04-12 2012-10-18 Boryung Pharmaceutical Co., Ltd. Antihypertensive pharmaceutical composition
AU2012296938A1 (en) 2011-08-12 2014-02-13 Boehringer Ingelheim Vetmedica Gmbh Funny current (IF) inhibitors for use in a method of treating and preventing heart failure in feline
WO2013147137A1 (ja) * 2012-03-30 2013-10-03 味の素株式会社 心不全の治療剤
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
WO2016073179A2 (en) * 2014-10-23 2016-05-12 The Trustees Of The University Of Pennsylvania Novel chronotherapy based on circadian rhythms
RU2616213C2 (ru) * 2015-07-10 2017-04-13 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте
KR102651292B1 (ko) * 2015-10-31 2024-03-25 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
CN105287550A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种缬沙坦/非洛地平复方制剂及其制备方法
JP7505024B2 (ja) * 2020-04-17 2024-06-24 ハニーブレインズ リミテッド ライアビリティ カンパニー 精神神経障害を処置するための組成物および方法
CN113730581A (zh) * 2020-05-28 2021-12-03 杭州起岸生物科技有限公司 钾atp通道调节剂在制备抗糖尿病肾病药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654372A (en) * 1986-01-10 1987-03-31 Warner-Lambert Company Method for using verapamil for treating stroke
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
DK0443983T3 (da) * 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
NZ242724A (en) 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
WO1993017682A1 (en) * 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
CA2139947C (en) * 1992-07-27 1998-06-30 Robert A. Volkmann Calcium channel blocking polypeptide from agelenopsis aperta
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
PT634175E (pt) * 1993-07-15 2001-06-29 Hoffmann La Roche Combinacao farmaceutica que contem um inibidor do sistema renina-angiotensina e o antagonista de endotelina
MX9603259A (es) * 1994-02-08 1997-03-29 Novartis Ag Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.
CA2184712A1 (en) * 1994-03-17 1995-09-21 Marc De Gasparo Treatment of diabetic nephropathy with valsartan
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
SK285863B6 (sk) 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín

Also Published As

Publication number Publication date
PL345897A1 (en) 2002-01-14
CN1312715A (zh) 2001-09-12
LU92992I2 (fr) 2016-05-09
WO2000002543A3 (en) 2000-06-29
IL140665A0 (en) 2002-02-10
DK1096932T3 (da) 2007-10-15
EP1870098A2 (en) 2007-12-26
CA2678722C (en) 2013-08-27
NL300290I1 (el) 2007-11-01
NL300290I2 (nl) 2008-11-03
PL194604B1 (pl) 2007-06-29
PT2322174E (pt) 2015-10-27
AU753486B2 (en) 2002-10-17
AU5034999A (en) 2000-02-01
CY2016006I1 (el) 2016-10-05
CZ304359B6 (cs) 2014-03-26
CY2007026I1 (el) 2009-11-04
SI1096932T1 (sl) 2008-04-30
CY1107779T1 (el) 2010-07-28
KR100550167B1 (ko) 2006-02-08
ES2289814T3 (es) 2008-02-01
ES2552639T3 (es) 2015-12-01
HK1036758A1 (en) 2002-01-18
HK1152897A1 (en) 2012-03-16
EP2322174A3 (en) 2011-07-27
FR16C0008I1 (el) 2016-04-15
CZ200187A3 (en) 2001-05-16
NZ509260A (en) 2003-09-26
EP1870098A3 (en) 2010-07-07
CY1116770T1 (el) 2016-10-05
NL300800I2 (el) 2016-07-27
CN1234357C (zh) 2006-01-04
SK312001A3 (en) 2001-06-11
DE122007000055I1 (de) 2007-12-13
WO2000002543A2 (en) 2000-01-20
RU2450813C2 (ru) 2012-05-20
DE69936992T2 (de) 2008-03-06
CN1733307A (zh) 2006-02-15
RU2243768C2 (ru) 2005-01-10
EP2322174B1 (en) 2015-09-23
ID27664A (id) 2001-04-19
ZA200100232B (en) 2002-04-09
NO331802B1 (no) 2012-04-10
TR200100062T2 (tr) 2001-06-21
CA2336822A1 (en) 2000-01-20
EP1096932B1 (en) 2007-08-29
NO20010113D0 (no) 2001-01-08
EP1096932A2 (en) 2001-05-09
KR20010079517A (ko) 2001-08-22
CA2678722A1 (en) 2000-01-20
SG142116A1 (en) 2008-05-28
DK2322174T3 (en) 2015-10-12
SK285863B6 (sk) 2007-10-04
PT1096932E (pt) 2007-09-21
HUP0102828A3 (en) 2002-11-28
IL213926A0 (en) 2011-07-31
LU91358I2 (fr) 2007-11-06
KR20040078140A (ko) 2004-09-08
NO2012013I1 (no) 2012-07-30
NO20010113L (no) 2001-03-09
CZ299429B6 (cs) 2008-07-23
SI2322174T1 (sl) 2015-12-31
DE69936992D1 (de) 2007-10-11
JP2002520274A (ja) 2002-07-09
HUP0102828A2 (hu) 2002-04-29
NO2012013I2 (no) 2014-10-27
CA2336822C (en) 2009-11-17
BE2016C011I2 (el) 2018-12-04
FR16C0008I2 (fr) 2018-06-08
NZ527598A (en) 2005-04-29
ATE371448T1 (de) 2007-09-15
IL140665A (en) 2012-12-31
CY2007026I2 (el) 2009-11-04
BR9912021A (pt) 2001-04-03
EP2322174A2 (en) 2011-05-18
HU229383B1 (en) 2013-11-28
RU2012110522A (ru) 2013-09-27

Similar Documents

Publication Publication Date Title
CY2016006I2 (el) Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους
CY2011010I1 (el) Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους
DE60141247D1 (de) Bandkassette und bandeinheit
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
FI971412A7 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä
DE69631473D1 (de) Weichgewebeverankerung
EE04190B1 (et) Asendatud bensopüraani derivaatide kasutamine põletiku raviks
ID27841A (id) Turunan-turunan biaril terapeutik
DE69911378D1 (de) Fluorierte ionomere und verwendung davon
DE69739642D1 (de) Feste orale Dosierungsformen enthaltend Valsartan und Hydrochlorothiazide
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
ID18679A (id) Penggunaan terapi lanjutan
ID21948A (id) Penggunaan 1-hidroksi-2piridon untuk pengobatan infeksi-infeksi kulit
DE69816744D1 (de) Orthopädisches Reibinstrument
DE60144529D1 (de) Bandkassette und bandeinheit
NO20010291D0 (no) Coadministrasjon av ACAT og MMP inhibitorer for behandling av aterosklerotiske sår
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
ID24922A (id) Terapi kombinasi untuk pengobatan aids
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
ID24521A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
IT1299811B1 (it) Dispositivo massaggiante
BR9604756A (pt) Banheira hospitalar
KR970060708U (ko) 발 맛사지기
ID29414A (id) Pengobatan depresi
KR960030478U (ko) 침대의 안마장치